CN118028146A - Pediococcus acidilactici, composition containing same and application of composition - Google Patents
Pediococcus acidilactici, composition containing same and application of composition Download PDFInfo
- Publication number
- CN118028146A CN118028146A CN202410038368.0A CN202410038368A CN118028146A CN 118028146 A CN118028146 A CN 118028146A CN 202410038368 A CN202410038368 A CN 202410038368A CN 118028146 A CN118028146 A CN 118028146A
- Authority
- CN
- China
- Prior art keywords
- pediococcus acidilactici
- composition
- strain
- acidilactici
- pediococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000191998 Pediococcus acidilactici Species 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 231100000678 Mycotoxin Toxicity 0.000 claims abstract description 18
- 239000002636 mycotoxin Substances 0.000 claims abstract description 18
- 238000004321 preservation Methods 0.000 claims abstract description 17
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 33
- 230000000813 microbial effect Effects 0.000 claims description 24
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 abstract description 25
- 238000006731 degradation reaction Methods 0.000 abstract description 25
- 230000012010 growth Effects 0.000 abstract description 13
- 239000002253 acid Substances 0.000 abstract description 10
- 239000003833 bile salt Substances 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 13
- 229930020125 aflatoxin-B1 Natural products 0.000 description 13
- MBMQEIFVQACCCH-UHFFFAOYSA-N trans-Zearalenon Natural products O=C1OC(C)CCCC(=O)CCCC=CC2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-UHFFFAOYSA-N 0.000 description 13
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 13
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 229940039696 lactobacillus Drugs 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 9
- -1 DON Chemical compound 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000009630 liquid culture Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 229930182566 Gentamicin Natural products 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- 229960002518 gentamicin Drugs 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 108010093965 Polymyxin B Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960003405 ciprofloxacin Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229920000024 polymyxin B Polymers 0.000 description 5
- 229960005266 polymyxin b Drugs 0.000 description 5
- 210000004767 rumen Anatomy 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229960001699 ofloxacin Drugs 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 238000009654 indole test Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXEYZZMDPRBKHU-UHFFFAOYSA-N 5-methylnonan-5-ylbenzene Chemical compound CCCCC(C)(CCCC)C1=CC=CC=C1 FXEYZZMDPRBKHU-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 206010057648 Cyclopia Diseases 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229930002954 deoxynivalenol Natural products 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- UVBUBMSSQKOIBE-DSLOAKGESA-N fumonisin B1 Chemical compound OC(=O)C[C@@H](C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N UVBUBMSSQKOIBE-DSLOAKGESA-N 0.000 description 1
- QZIADBYRQILELJ-UHFFFAOYSA-N fumonisin B1 Natural products CCCCC(C)C(OC(=O)CC(CC(=O)O)C(=O)O)C(C)(CC(C)CC(O)CCCCC(O)CC(O)C(C)N)OC(=O)CC(CC(=O)O)C(=O)O QZIADBYRQILELJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229930183344 ochratoxin Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to Pediococcus acidilactici Pediococcus acidilactici HZ, a composition containing the same and application thereof. The Pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection. The composition comprises at least one of Pediococcus acidilactici and a culture of the strain. The invention has the advantages that: (1) high-efficiency degradation of mycotoxin. (2) strong growth capacity, acid resistance and bile salt resistance. (3) safe and has better probiotics.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to Pediococcus acidilactici Pediococcus acidilactici HZ, a composition containing the same and application thereof.
Background
The feed and the raw materials thereof are easy to mildew and generate mould in the process of processing, storing and transporting. The mould not only reduces the nutritive value of the feed and affects the palatability, resulting in the reduction of the feed intake of livestock and poultry, but also causes the growth arrest of animals, the reduction of immunity, the reduction of production performance and even poisoning and death.
Among the mycotoxins commonly found in daily life are AFB1, ZEA, DON, T-2 toxin (T-2), ochratoxin (OTA), fumonisin B1 (FB 1), cyclopia aninic acid (CPA), and the like. The source, physiological response and clinical symptoms of different mycotoxins are all different: wherein the AFB1 is derived from Aspergillus flavus, and can damage animal liver, inhibit immunity, and cause cancer and death of animals and human after long-term exposure. ZEA is an estrogenic toxin produced by Fusarium, and poisoning is manifested by reduced feed conversion rate, organ weight change, reduced animal fertility, abnormal behavior, etc. DON and T-2 are derived from Fusarium, respectively type B and type A, and can directly damage animal digestive tract mucosa, and are generally manifested by anorexia, hemorrhage, emesis, diarrhea, etc. OTA is derived from Aspergillus and Penicillium, and is an immunosuppressant, teratogen and nephrotoxic compound, and poisoning can cause renal cortex degeneration, medullary hemorrhage and other diseases, and the target organ is kidney.
At present, diseases caused by bacteria and fungi are generally treated by antibiotics, but most bacteria and fungi generate drug resistance to different degrees due to abuse of antibiotics, so that food and drug residue phenomenon becomes a serious public health and food safety problem, and lactobacillus has the advantages of high detoxification efficiency, strong specificity, no pollution and the like, and can be used as a potential antibiotic substitute. Meanwhile, the lactobacillus can also improve intestinal microecology balance, promote animal growth and development, improve organism immunity, resist bacteria and prevent diseases, and has the functions of nutrition, health care and the like.
Disclosure of Invention
The invention aims to provide Pediococcus acidilactici which has the advantages of high efficiency in degrading mycotoxin, good probiotics, strong growth capacity, acid resistance, bile salt resistance and no hemolysis, a composition containing the same and application.
Preservation description:
classification naming: pediococcus acidilactici HZ49,49;
Preservation time: 2023, 11, 01;
Preservation unit: china center for type culture Collection; preservation address: university of Chinese Wuhan
Preservation number: cctccc NO: m20232103.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
In a first aspect, the invention provides a pediococcus acidilactici.
A pediococcus acidilactici, which is Pediococcus acidilactici HZ49,49 with a preservation number of CCTCC NO: m20232103, deposited in China center for type culture Collection.
In a second aspect, the invention provides a microbial preparation.
A microbial preparation comprising pediococcus acidilactici or a culture of said strain.
The pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection.
In a third aspect, the present invention provides a composition.
A composition comprising at least one of pediococcus acidilactici and a culture of said strain;
the strain culture includes but is not limited to Pediococcus acidilactici fermentation broth, fermentation precipitate or lyophilized powder.
The pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection.
Further, the composition is a microecological or pharmaceutical formulation.
Further, the composition is a probiotic.
Further, the composition also contains substances which help to maintain the viability of Pediococcus acidilactici; the composition also contains other probiotics and/or prebiotics.
In a fourth aspect, the present invention provides the use of a pediococcus acidilactici of the first aspect or a microbial preparation of the second aspect or a composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for degrading mycotoxins.
In a fifth aspect, the invention provides another use of the pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for a probiotic.
In a sixth aspect, the present invention provides a third use of the pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for feed fermentation.
In the fourth, fifth and sixth aspects, the pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is cctccc NO: m20232103, deposited in China center for type culture Collection.
In a seventh aspect, the invention provides an animal feed.
An animal feed comprising pediococcus acidilactici of the first aspect;
and/or a fermentation product of pediococcus acidilactici of the first aspect;
and/or the microbial preparation of the second aspect;
And/or the composition of the third aspect.
The composition of Pediococcus acidilactici provided by the invention can contain substances which help to keep the activity of Pediococcus acidilactici. The substance (such as protectant) for maintaining activity of Pediococcus acidilactici can be any one or combination of cysteine, glutathione, butyl hydroxy anisole, dibutyl methyl toluene, tocopherol, bamboo leaf antioxidant, D-isoascorbic acid and its sodium salt, sodium ascorbate, calcium ascorbate, phospholipid, vitamin C (ascorbic acid), and vitamin E.
The composition of Pediococcus acidilactici provided by the invention can contain other probiotics, wherein the probiotics can be selected from: any one or combination of lactobacillus, bifidobacterium and lactobacillus acidophilus.
The composition of pediococcus acidilactici provided by the invention can contain prebiotics, wherein the prebiotics can be any one or a combination of fructo-oligosaccharide (FOS), galacto-oligosaccharide (GOS), xylo-oligosaccharide (XOS), lactulose-oligosaccharide (LACT), soybean Oligosaccharide (SOS), inulin (Inulin) and oligosaccharide.
The pediococcus acidilactici provided by the invention is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited with China center for type culture Collection, 11 and 8 of 2023. The strain was isolated from the rumen of Qinghai Tibetan sheep. Pediococcus acidilactici (Pediococcus acidilactici HZ49,49) can degrade mycotoxin with high efficiency and has probiotic properties; can be used as feed additive or strain fermented feed, and can improve feed utilization rate.
The pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention can degrade mycotoxin efficiently, and degradation rates of the pediococcus acidilactici HZ49 on AFB1 (Aaflatoxin B1, aflatoxin B1), DON (Deoxynivalenol, vomitoxin), ZEA (Zearalenone) and GLUS (thioglucoside) are respectively 56.58%, 64.12%, 61.37% and 79.64%. Pediococcus acidilactici HZ49 had an average degradation rate of 65.43 for AFB1, DON, ZEA and GLUS.
The pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention enters the logarithmic phase after being inoculated for 4 hours, the fermentation time is shortest, the stronger the environmental adaptability is, and the more the vitality is. Can grow normally in an acidic environment with pH of 3.5, and has complete tolerance to 0.1 percent of bile salt environment and high acid and bile salt tolerance. Is completely tolerant to 2.0% NaCl concentration.
The pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention has no hemolytic symptoms. Is moderately sensitive to erythromycin, insensitive to streptomycin and gentamicin, highly sensitive to penicillin, insensitive to tetracycline, insensitive to polymyxin B, and insensitive to ciprofloxacin. Has strong antibacterial performance on salmonella and escherichia coli and has extremely strong antibacterial performance on staphylococcus aureus. The strain is safe and has good probiotics.
The invention separates and screens lactobacillus which can efficiently degrade mycotoxin and has probiotics from the rumen of Qinghai-Tibetan sheep, and the lactobacillus ferments the feed, so that the lactobacillus can degrade various mycotoxins in the feed raw material, improve the safety of the feed, increase the utilization of some unconventional feed raw materials, and has great prospect in the application of fermented feed taking unconventional feed as raw material.
Compared with the prior art, the pediococcus acidilactici, the composition containing the pediococcus acidilactici and the application thereof have the advantages that:
(1) And the mycotoxin is efficiently degraded.
(2) Strong growth ability, acid resistance and bile salt resistance.
(3) Safe and has good probiotic property.
Drawings
FIG. 1 shows colony morphology of Pediococcus acidilactici (Pediococcus acidilactici HZ) strain and gram staining of the strain (left panel) provided by the invention (right panel).
FIG. 2 is an agarose gel electrophoresis chart (fluorescent band No. 14) of genomic DNA of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention.
FIG. 3 is an electrophoresis chart (fluorescent band No. 14) of the amplified product of genomic DNAPCR of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the present invention.
Fig. 4 is a phylogenetic tree of pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention.
FIG. 5 is a graph showing the growth of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention.
Fig. 6 is an acidogenesis curve of pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention.
FIG. 7 shows the growth of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention at different pH conditions.
FIG. 8 shows the growth of Pediococcus acidilactici (Pediococcus acidilactici HZ) according to the present invention at different bile salt concentrations.
FIG. 9 shows the growth of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the invention at different concentrations of NaCl.
FIG. 10 shows the results of a Pediococcus acidilactici (Pediococcus acidilactici HZ) hemolysis test provided by the invention.
FIG. 11 shows the results of a drug susceptibility test of Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the present invention against 8 antibiotics.
FIG. 12 is a graph of the detoxification of AFB1, DON, ZEA and GLUS by Pediococcus acidilactici (Pediococcus acidilactici HZ) provided by the present invention.
In fig. 2 and 3, M represents DL 2000Marker; the fluorescent strip No. 14 is Pediococcus acidilactici (Pediococcus acidilactici HZ).
In fig. 11, 1 represents polymyxin B;2 represents ciprofloxacin; 3 represents tetracycline; 4 represents gentamicin; 5 represents erythromycin; 6 represents ofloxacin; 7 represents penicillin; 8 represents streptomycin.
Detailed Description
The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention in order to provide a better understanding of the technical solution of the present invention to those skilled in the art.
In a first aspect, the invention provides a pediococcus acidilactici.
A pediococcus acidilactici, which is Pediococcus acidilactici HZ49,49 with a preservation number of CCTCC NO: m20232103, deposited in China center for type culture Collection.
In a second aspect, the invention provides a microbial preparation.
A microbial preparation comprising pediococcus acidilactici or a culture of said strain.
The pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection.
In a third aspect, the present invention provides a composition.
A composition comprising at least one of pediococcus acidilactici and a culture of said strain;
the strain culture includes but is not limited to Pediococcus acidilactici fermentation broth, fermentation precipitate or lyophilized powder.
The pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection.
Further, the composition is a microecological or pharmaceutical formulation.
Further, the composition is a probiotic.
Further, the composition also contains substances which help to maintain the viability of Pediococcus acidilactici; the composition also contains other probiotics and/or prebiotics.
In a fourth aspect, the present invention provides the use of a pediococcus acidilactici of the first aspect or a microbial preparation of the second aspect or a composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for degrading mycotoxins.
In a fifth aspect, the invention provides another use of the pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for a probiotic.
In a sixth aspect, the present invention provides a third use of the pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect.
Use of pediococcus acidilactici of the first aspect or the microbial preparation of the second aspect or the composition of the third aspect for the preparation of a composition for feed fermentation.
In the fourth, fifth and sixth aspects, the pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is cctccc NO: m20232103, deposited in China center for type culture Collection.
In a seventh aspect, the invention provides an animal feed.
An animal feed comprising pediococcus acidilactici of the first aspect;
and/or a fermentation product of pediococcus acidilactici of the first aspect;
and/or the microbial preparation of the second aspect;
And/or the composition of the third aspect.
Example 1
Isolation and identification of Pediococcus acidilactici Pediococcus acidilactici HZ49
1. Morphological identification
Strains of lactic acid bacteria separated from rumen of Qinghai-Tibetan sheep are respectively inoculated into MRS solid and liquid culture media, and single colony size, shape, surface characteristics, edge shape, color, transparency degree and the like are observed after 24h culture at 37 ℃. The inoculating loop picks a proper amount of culture at the center of the glass slide, carefully coats the glass slide, covers the glass slide, and observes the shape and size of the strain under an optical microscope.
As shown in FIG. 1 and Table 1, the strains obtained by screening are suspected to be lactobacillus strains, the strains are positive through gram-positive test reaction, the strains are determined to be gram-positive bacteria, and the catalase test reaction is negative. Gram positive bacteria appear purple in color under a microscope, and the shape of the strain appears as a sphere. The strain is milky white; the bacterial strain is round micro-protuberance, the colony surface is smooth and moist, and the edge is neat.
TABLE 1 morphological characteristics of lactic acid bacteria
"+": Positive; "-": negative.
2. Physiological and biochemical identification
Performing partial physiological and biochemical experiments with a bacterial physiological and biochemical identification kit, wherein the partial physiological and biochemical experiments comprise esculin, mannitol, sucrose, maltose, cellobiose, salicin, sorbitol and raffinose; the strains were initially identified by the catalase test, the motility test, the hydrogen sulfide test, the glucose gas production test, the gelatin liquefaction test and the indole test with reference to the manual of bacteriology of Bojk system, GB 4789.35-201645.
As shown in Table 2, the test showed that the strain did not produce gas, the indole test, the catalase test, and the hydrogen sulfide test were negative, and the gelatin was not liquefied. The final identification result is determined by combining morphological analysis and 16S rRNA gene segment sequence analysis results.
TABLE 2 physiological and biochemical characteristics of lactic acid bacteria
"+": Positive; "-": negative.
3. Molecular biological identification
Extracting lactobacillus genome DNA with OMEGA bacteria genome DNA extraction kit. The 16S rRNA gene amplification primers were synthesized by Shanghai Biotechnology Co., ltd, and the sequences were as follows: 16S F, 5'-AGA GTT TGA TCC TGG CTC AG-3';16S R is 5'-GGT TAC CTT GTT ACG ACT T-3'. The genomic DNA prepared above was used as a template for PCR amplification, and PCR amplification was performed using 50. Mu.L of the reaction system. The cycle parameters are as follows: pre-denaturation at 95 ℃ for 1min, denaturation at 95 ℃ for 30s, annealing at 55 ℃ for 30s, extension at 72 ℃ for 2min, extension at 72 ℃ for 5min at the end, 30 cycles, and sequencing of the amplified product. And (3) comparing sequencing results through splicing treatment, selecting typical strain sequences with the similarity of more than 97.00% by BLAST, and constructing a phylogenetic tree by using MEGA software.
As shown in figures 2 and 3, the single fluorescence band appears at 1500bp through electrophoresis detection and gel imaging analysis of the amplified fragment, the amplified product has good integrity, no degradation, no tailing phenomenon and no non-specific amplification phenomenon, and meets the sequencing requirement. Sequencing results were compared by Blast and phylogenetic tree construction (FIG. 4) to find HZ49 to be Pediococcus acidilactici. HZ49 was determined to be Pediococcus acidilactici from Table 3 and FIG. 4.
TABLE 3 homology alignment of lactic acid bacteria 16S rRNA sequences
Example 2
Probiotic properties of Pediococcus acidilactici Pediococcus acidilactici HZ49
1. Determination of growth Capacity and acid production Capacity
The Pediococcus acidilactici HZ49 bacterial liquid is respectively inoculated into an MRS liquid culture medium according to the inoculation amount of 3 percent, is cultivated at the constant temperature of 37 ℃, and is respectively repeated for 3 times in each group at 0h, 2h, 4h, 6h, 8h, 12h, 16h, 24h, 36h and 48h, the blank culture medium is used as a control, the OD 600 value and the pH value are measured, the bacterial liquid cultivation time is used as an abscissa, and the absorbance value and the pH value are used as an ordinate to draw a growth curve and an acidogenic curve.
As shown in the growth curve of FIG. 5, the HZ49 strain is in a slow period between 0 and 4 hours, enters a logarithmic growth phase after 4 hours of inoculation, and has short fermentation time, strong environmental adaptability and vigorous vitality; HZ49 strain is in a stable period in 24-48 h, and OD 600 value in 48h is 1.6, so that the strain has stronger fermentation activity.
As shown in the acid-producing curve of FIG. 6, the pH of the HZ49 strain gradually tended to stabilize from the steady state to the rapid decrease phase, and the pH of the culture medium began to decrease as the strain entered the logarithmic growth phase, and the pH began to stabilize again after the strain entered the steady state. HZ49 strain enters logarithmic phase at 4h, pH rapidly drops after entering logarithmic phase, and enters stationary phase at 24 h. The pH value is below 4.5 in 48 hours, which shows that the acid production performance is good.
2. Acid and bile salt tolerance
Inoculating Pediococcus acidilactici HZ49 bacterial liquid into MRS liquid culture media with pH values of 2.5, 3.0, 3.5, 4.0 and 6.0 according to 1% inoculum size, culturing at 37 ℃ for 24 hours, and measuring the OD 600 value of the bacterial liquid; inoculating into MRS liquid culture medium with 0.0%, 0.1%, 0.2% and 0.3% of ox gall salt concentration according to 1% inoculum size, culturing for 24 hr, respectively measuring OD 600 value of bacterial liquid, and using blank culture medium with same acidity and gall salt concentration as control.
As shown in FIG. 7, pediococcus acidilactici HZ49 grew substantially normally in acidic environments at pH3.5 and pH4.0, was substantially intolerant to acidic environments at pH3.0 and pH2.5, and was arrested.
As shown in fig. 8, pediococcus acidilactici HZ49 was completely tolerant to 0.1% bile salt environment; pediococcus acidilactici HZ49 growth was inhibited at 0.2% bile salt.
3. Osmotic pressure resistance
2.0%, 4.0%, 6.0% And 8.0% NaCl are respectively added into an MRS liquid culture medium, the Pediococcus acidilactici HZ49 bacterial liquid is inoculated into the MRS liquid culture medium with different NaCl concentrations according to 1% inoculum size, after the MRS liquid culture medium is cultured for 24 hours at the constant temperature of 37 ℃, the OD 600 value of each bacterial liquid is respectively measured, and 3 replicates of each bacterial liquid are used as a control by using a blank culture medium with the same NaCl concentration.
As shown in FIG. 9, pediococcus acidilactici HZ49 was completely tolerant to 2.0% NaCl concentration, the OD value was slowly decreased at 4.0% NaCl concentration, and inhibition was performed in an environment of higher than 6.0% NaCl.
4. Safety inspection
(1) Lactic acid bacteria hemolysis test
All screened strains were streaked on Columbia platelets and incubated for 24-48 h. The presence or absence of a hemolytic loop around the colonies was observed: alpha-hemolysis, beta-hemolysis and gamma-hemolysis, and recorded by photographing.
As shown in fig. 10, pediococcus acidilactici HZ49 did not show symptoms of hemolysis (gamma hemolysis) after 48h incubation.
(2) Lactic acid bacteria antibiotic susceptibility test
A drug sensitivity test of 8 antibiotics was performed on Pediococcus acidilactici HZ49 strain using a drug sensitivity paper sheet method. Polymyxin B (Polymycin B, PB); ciprofloxacin (Ciorofloxacin, CIP); tetracyclines (TETRACYCLINE, TE); gentamicin (GENTAMICIN, GEN); erythromycin (Erythromycin, E); ofloxacin (Ofloxacin, OFX); penicillin (Penicillin, P); streptomycin (streptomycin, S).
As shown in FIG. 11, pediococcus acidilactici HZ49 was moderately sensitive to erythromycin, insensitive to streptomycin and gentamicin, highly sensitive to penicillin, insensitive to tetracycline, insensitive to polymyxin B, and insensitive to ciprofloxacin.
(3) Determination of bacteriostasis of lactic acid bacteria
The diameter of the inhibition zone of the strain fermentation supernatant to pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus and the like is measured by adopting an oxford cup method.
As shown in Table 4, pediococcus acidilactici HZ49 has strong antibacterial performance on salmonella and escherichia coli and has extremely strong antibacterial performance on staphylococcus aureus.
TABLE 4 antibacterial results of lactic acid bacteria
"+" Indicates that the diameter of the inhibition zone is 9.0-12.99 mm; "++" indicates that the diameter of the inhibition zone is 13.0-16.99 mm; "++ + +" indicates that the diameter of the inhibition zone is 17.0-19.99 mm; "+". ++'s indicating bacteriostasis the diameter of the ring is more than or equal to 20mm
Example 3
Degradation of mycotoxins by Pediococcus acidilactici Pediococcus acidilactici HZ49
1. Mycotoxin degradation rate test
The degradation effect of Pediococcus acidilactici HZ49 on AFB1, DON, ZEA and GLUS was tested, and the degradation rate of 4 mycotoxins was determined after 72h fermentation. The results are shown in Table 5.
As is clear from Table 5, pediococcus acidilactici HZ49 has a degradation rate of 60.47% for AFB1 and 48.34% for DON; the degradation rate of ZEA is 32.31%; the degradation rate of GLUS is 18.46%.
TABLE 5 degradation rates of lactic acid bacteria on four toxins
2. Lactic acid bacteria detoxification curve
Pediococcus acidilactici HZ49 is inoculated into MRS liquid culture medium according to 1%, cultured for 24 hours at 37 ℃ and then respectively cultured with four toxins, toxin content is measured in time periods of 0h, 2h, 4h, 8h, 12h, 1d, 3d, 7d and 14d, the culturing time is taken as an abscissa, the degradation rate is taken as an ordinate, a detoxification curve is drawn, and the change condition of the toxin degradation rate in different time periods is analyzed.
As shown in fig. 12, the degradation rate of pediococcus acidilactici HZ49 on all four toxins increases with time, and the degradation rate on AFB1 changes as follows: slowly rises before 12h, rapidly rises after 12h, and gradually reaches a stable stage after 7 d. The degradation rate change trend of DON is as follows: slowly rises before 12h, and gradually goes to a stable stage after 12 h. The degradation rate change trend of the ZEA is as follows: slowly rises in 2-12 h, and the degradation rate rapidly rises in 12-24 h. The degradation rate change trend of GLUS is as follows: slowly rises in 2-12 h, the degradation rate rapidly rises in 12-24 h, and the degradation rate is 43.41% in 12 h. At fermentation 14d, the degradation rates of Pediococcus acidilactici HZ49 on AFB1, DON, ZEA and GLUS were 56.58%, 64.12%, 61.37% and 79.64%, respectively.
In summary, as fermentation time increases, pediococcus acidilactici HZ49 has higher degradation rates for AFB1, DON, ZEA and GLUS, wherein the average degradation rate for AFB1, DON, ZEA, GLUS can reach 65.43% at the time of fermentation 14 d.
The invention provides Pediococcus acidilactici Pediococcus acidilactici HZ, the preservation number is CCTCCNO: m20232103, deposited with China center for type culture Collection, 11 and 8 of 2023. The strain was isolated from the rumen of Qinghai Tibetan sheep.
Pediococcus acidilactici HZ49, the stronger the environmental suitability, the more vigorous the vitality; acid and bile salts are highly tolerant; no hemolysis symptoms; has strong antibacterial performance on salmonella and escherichia coli and has extremely strong antibacterial performance on staphylococcus aureus. The composition can be efficiently degraded to AFB1, DON, ZEA and GLUS, and Pediococcus acidilactici HZ49 is moderately sensitive to erythromycin, is insensitive to streptomycin and gentamicin, is highly sensitive to penicillin, is insensitive to tetracycline, is insensitive to polymyxin B and is insensitive to ciprofloxacin. The strain is safe and has good probiotics. Can be used as feed additive or strain fermented feed, and can degrade mycotoxin in feed and improve feed utilization rate.
The invention separates and screens lactobacillus which can efficiently degrade mycotoxin and has probiotics from the rumen of Qinghai-Tibetan sheep, and the lactobacillus ferments the feed, so that the lactobacillus can degrade various mycotoxins in the feed raw material, improve the safety of the feed, increase the utilization of some unconventional feed raw materials, and has great prospect in the application of fermented feed taking unconventional feed as raw material.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various modifications can be made to the technical solutions of the present invention within the scope of the technical concept of the present invention, and these simple modifications all fall within the scope of the present invention.
In addition, the specific features and steps described in the foregoing embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described in detail.
Moreover, any combination of the various embodiments of the invention can be made without departing from the spirit of the invention, which should also be considered as disclosed herein.
Claims (10)
1. The pediococcus acidilactici is Pediococcus acidilactici HZ, and the preservation number is CCTCC NO: m20232103, deposited in China center for type culture Collection.
2. A microbial preparation, characterized in that: the microbial preparation comprises Pediococcus acidilactici or a culture of the strain.
3. A composition characterized by: the composition comprises at least one of Pediococcus acidilactici and a culture of the strain;
the strain culture includes but is not limited to Pediococcus acidilactici fermentation broth, fermentation precipitate or lyophilized powder.
4. A composition according to claim 3, characterized in that: the composition is a microecological or pharmaceutical formulation.
5. The composition of claim 4, wherein: the composition is a probiotic.
6. A composition according to claim 3, characterized in that: the composition also contains substances which help to maintain the viability of Pediococcus acidilactici; the composition also contains other probiotics and/or prebiotics.
7. Use of pediococcus acidilactici according to claim 1, or the microbial preparation according to claim 2, or the composition according to any one of claims 3 to 6, for the preparation of a composition for degrading mycotoxins.
8. Use of pediococcus acidilactici according to claim 1, or the microbial preparation according to claim 2, or the composition according to any one of claims 3 to 6, for the preparation of a composition for a probiotic.
9. Use of pediococcus acidilactici according to claim 1, or the microbial preparation according to claim 2, or the composition according to any one of claims 3 to 6, for the preparation of a composition for feed fermentation.
10. An animal feed characterized by: the animal feed comprises pediococcus acidilactici according to claim 1 and/or a fermentation product of pediococcus acidilactici and/or a microbial preparation according to claim 2 and/or a composition according to any one of claims 3 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410038368.0A CN118028146A (en) | 2024-01-10 | 2024-01-10 | Pediococcus acidilactici, composition containing same and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410038368.0A CN118028146A (en) | 2024-01-10 | 2024-01-10 | Pediococcus acidilactici, composition containing same and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118028146A true CN118028146A (en) | 2024-05-14 |
Family
ID=90990237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410038368.0A Pending CN118028146A (en) | 2024-01-10 | 2024-01-10 | Pediococcus acidilactici, composition containing same and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118028146A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117925457A (en) * | 2024-01-10 | 2024-04-26 | 青海大学 | Lactic acid bacteria composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034163A (en) * | 2017-05-23 | 2017-08-11 | 北京市农林科学院 | A kind of novel lactic piece coccus and its application |
| CN110250396A (en) * | 2019-07-24 | 2019-09-20 | 天津科技大学 | Pediococcus acidilactici CGMCC 1.4 is inhibiting the application in aspergillus flavus |
| CN117925457A (en) * | 2024-01-10 | 2024-04-26 | 青海大学 | Lactic acid bacteria composition and application thereof |
-
2024
- 2024-01-10 CN CN202410038368.0A patent/CN118028146A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107034163A (en) * | 2017-05-23 | 2017-08-11 | 北京市农林科学院 | A kind of novel lactic piece coccus and its application |
| CN110250396A (en) * | 2019-07-24 | 2019-09-20 | 天津科技大学 | Pediococcus acidilactici CGMCC 1.4 is inhibiting the application in aspergillus flavus |
| CN117925457A (en) * | 2024-01-10 | 2024-04-26 | 青海大学 | Lactic acid bacteria composition and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117925457A (en) * | 2024-01-10 | 2024-04-26 | 青海大学 | Lactic acid bacteria composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hossain et al. | Identification and growth characterization of a novel strain of Saccharomyces boulardii isolated from soya paste | |
| CN110577912B (en) | Lactobacillus gasseri and application thereof in preparing fermented milk | |
| CN110157645B (en) | Lactobacillus salivarius Y4 and application thereof | |
| CN112725219B (en) | Bifidobacterium adolescentis strain and application thereof | |
| CN118028146A (en) | Pediococcus acidilactici, composition containing same and application of composition | |
| CN118086101A (en) | Pediococcus pentosaceus, composition containing same and application of composition | |
| CN117866828A (en) | Pediococcus acidilactici, composition containing same and application of composition | |
| CN114085789B (en) | Pediococcus pentosaceus MA.WTPQJ01 and application thereof | |
| CN118028145A (en) | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis | |
| CN114134083B (en) | Bacillus bailii and application thereof | |
| CN117925457A (en) | Lactic acid bacteria composition and application thereof | |
| CN115820498A (en) | Lactobacillus plantarum YJ2406 and application thereof | |
| CN110028560B (en) | Bacteriocin produced by bacillus coagulans and application thereof | |
| CN113088468B (en) | Lactobacillus casei Ma. GLRGJ1 and application thereof | |
| CN111484958B (en) | Lactobacillus plantarum with ETEC (ethylene-tetra-ethyl-carbonate) inhibition effect, fermentation product and application thereof | |
| CN117143767B (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK capable of regulating intestinal flora and application thereof | |
| CN104789497A (en) | Acid-resistant and bile-salt-resistant Lactobacillus strain as well as screening method and application thereof | |
| CN109897800B (en) | Selenium-rich enterococcus durans A8-1 and application thereof | |
| CN114806944B (en) | Lactobacillus plantarum LP11, fermentation broth thereof, and preparation method and application thereof | |
| CN116478859A (en) | Lactic acid bacteria and microorganism preparation capable of tolerating hypochlorous acid water and application thereof | |
| CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
| CN114657082B (en) | Lactococcus lactis and application thereof | |
| CN111518716B (en) | Lactobacillus plantarum and application thereof | |
| CN109161501B (en) | Feeding bacillus licheniformis and application thereof | |
| CN113980838A (en) | Bacillus subtilis capable of efficiently and directionally expressing bacteriocin M6 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |